The 2025 Suzhou CMC Conference was held on August 1st and 2nd, 2025, and Renfu Tianrui Pharmaceutical was invited to participate in this industry exchange event. During the conference, the company won two awards: the CMC "2025 China Good Raw Material" award and the "Yao Rong Quan 2025 Ecological Partner" award, thanks to its stable product quality and professional service philosophy. This is both an affirmation of our past work and provides new impetus for the company's future development in related fields.
Yichang Tianrui Biopharmaceutical Co., Ltd. (Renfu Tianrui Pharmaceutical) was established on November 15, 2022. Located in Baiyang Bio-industry Park, Yichang High-tech Development Zone, Hubei Province, its parent company is Yichang Renfu Pharmaceutical Co., Ltd., a designated research and production enterprise for narcotic drugs and a national key high-tech enterprise. The company owns two national Class 1 new drugs, and its narcotic drugs account for more than 60% of the domestic market share. The company has more than 8,000 employees and achieved sales revenue of RMB 8.7 billion in 2024.
Renfu Tianrui Pharmaceutical is a biopharmaceutical company mainly engaged in the research, development, production, and sales of comprehensive services for high-end pharmaceutical raw materials (including intermediates). With a total investment of 2 billion yuan and a total land area of 330 mu, it is designed to have 13 GMP workshops and will be constructed in three phases. Currently, the second phase of the project has been completed, with an investment of 800 million yuan, and there are two GMP commercial workshops and nine production lines. It undertakes raw material CMO and CDMO businesses and has a research and development center built according to the highest domestic standards. It will achieve integrated and scaled research, development, production, and sales, aiming to become a world-class provider of high-end pharmaceutical raw materials.
Renfu Tianrui Pharmaceutical has launched eight star products, including Marbovec and Late Mo Wei. These products have won widespread praise in the market for their excellent quality, demonstrating the company's technological capabilities and production processes, and providing reliable raw material support for numerous partners.
In addition, to further expand its business scope and better meet market demand, Renfu Tianrui Pharmaceutical will subsequently launch a series of veterinary drug raw material products, including Flunixin Meglumine, Artemether Hydrochloride, Alfason, and Zolazepam Hydrochloride. These products will continue the company's consistent high-quality standards and contribute to the progress of the veterinary drug industry.
In the future, Renfu Tianrui Pharmaceutical will continue to uphold a rigorous and pragmatic attitude, actively integrate into the industry ecosystem, and continuously improve its own strength through exchange and practice, contributing more to the development of the industry!
